Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype

Blood Cells, Molecules, and Diseases

Volumn 44, Issue 4, 2010, Pages 229-232

  Landburg, P P ^a,b,c   Teerlink, T ^d   Biemond, B J ^e   Brandjes, D P M ^c   Muskiet, F A J ^f   Duits, A J ^a   Schnog, J B ^a,b,c  

^a Red Cross Blood Bank Foundation Curaçao   (Netherlands Antilles)

^b Sint Elisabeth Hospital   (Netherlands Antilles)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Asymmetric dimethylarginine; Hemolysis; Sickle cell disease

Indexed keywords

LACTATE DEHYDROGENASE; N(G),N(G) DIMETHYLARGININE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; AVASCULAR NECROSIS; BETA THALASSEMIA; CHOLELITHIASIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HEMOLYSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATHOPHYSIOLOGY; PHENOTYPE; PRIAPISM; PRIORITY JOURNAL; RETINOPATHY; SICKLE CELL ANEMIA;

ADULT; ALBUMINURIA; ANEMIA, SICKLE CELL; ARGININE; BETA-THALASSEMIA; CHOLELITHIASIS; FEMALE; HEMOLYSIS; HUMANS; HYPERTENSION, PULMONARY; LEG ULCER; MALE; MIDDLE AGED; NITRIC OXIDE; OSTEONECROSIS; PHENOTYPE; PRIAPISM; RETINAL DISEASES; SICKLE CELL TRAIT; YOUNG ADULT;

EID: 77950297065     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.02.005     Document Type: Article

References (25)

1. Kato G.J., Hebbel R.P., Steinberg M.H., Gladwin M.T. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am. J. Hematol. 2009, 84(9):618-625.
2. Wood K.C., Hsu L.L., Gladwin M.T. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic. Biol. Med. 2008, 44(8):1506-1528.
3. Morris C.R., Kato G.J., Poljakovic M., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294(1):81-90.
4. Reiter C.D., Wang X., Tanus-Santos J.E., et al. Cell-free hemoglobin limits nitric oxide in sickle cell disease. Nat Med 2002, 8(12):1383-1389.
5. Schnog J.B., Jager E.H., van der Dijs F.P., et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann. Hematol. 2004, 83:371-375.
6. Kato G.J., Gladwin M.T., Steinberg M.H. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007, 21:37-47.
7. Schnog J.B., Teerlink T., van der Dijs F.P., et al. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann. Hematol. 2005, 84:282-286.
8. Landburg P.P., Teerlink T., van Beers E.J., et al. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. Haematologica 2008, 93(9):1410-1412.
9. Kato G.J., Wang Z., Machado R.F., et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br. J. Haematol. 2009, 145(4):506-513.
10. van Beers E.J., van Tuijn C.F. Mac Gillavry MR, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica 2008, 93(5):757-760.
11. Stuart M.J., Setty B.N. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999, 94:1555-1560.
12. Teerlink T., Nijveldt R.J., de Jong S., van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal. Biochem. 2002, 303(2):131-137.
13. de Jong S., Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal. Biochem. 2006, 353(2):287-289.
14. Teerlink T. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 15(851(1-2)):21-29.
15. Landburg P.P., Teerlink T., Muskiet F.A., et al. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am. J. Hematol. 2008, 83(7):577-579.
16. Taylor J.G., Nolan V.G., Mendelsohn L., et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008, 3(5):e2095.
17. Kato G.J., McGowan V., Machado R.F., et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006, 107(6):2279-2285.
18. Zakynthinos E., Kiropoulos T., Gourgoulianis K., Filippatos G. Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. Heart Lung 2008, 37(4):275-285.
19. Fijalkowska A., Kurzyna M., Torbicki A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129(5):1313-1321.
20. Machado R.F., Anthi A., Steinberg M.H., et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006, 19(296(3)):310-318.
21. Voskaridou E., Tsetsos G., Tsoutsias A., et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007, 92(6):738-743.
22. Covitz W., Espeland M., Gallagher D., et al. The heart in sickle cell anemia. The Cooperative Study of Sickle Cell disease (CSSCD). Chest 1995, 108(5):1214-1219.
23. van Beers E.J., Nur E., Schaefer-Prokop C.M., et al. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. Am. J. Hematol. 2008, 83(11):850-854.
24. Gordeuk V.R., Sachdev V., Taylor J.G., et al. Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am. J. Hematol. 2008, 83(1):15-18.
25. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004, 26(350(9)):886-895.